Relationship between hemorheology and endothelial dysfunction in renal transplant patients receiving calcineurin inhibitors

Journal of Nephrology

Volumn 26, Issue 5, 2013, Pages 931-940

  Akoglu, Hadim ^a   Seringec, Nurten ^a   Yildirim, Tolga ^a   Yilmaz, Rahmi ^a   Okutucu, Sercan ^a   Turkmen, Ercan ^a   Evranos, Banu ^a   Kaya, Ergun B ^a   Dikmenoglu, Neslihan ^a   Arici, Mustafa ^a   Erdem, Yunus ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cyclosporin A; Endothelial dysfunction; Hemorheology; Renal transplantation; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; FIBRINOGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTERY DILATATION; ARTICLE; BLOOD RHEOLOGY; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; FLOW MEDIATED DILATION; HEMATOCRIT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PLASMA VISCOSITY; SIDE EFFECT; ADVERSE EFFECTS; BLOOD VISCOSITY; CASE CONTROL STUDY; DRUG EFFECTS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; BLOOD VISCOSITY; BRACHIAL ARTERY; CALCINEURIN INHIBITORS; CASE-CONTROL STUDIES; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; ERYTHROCYTE AGGREGATION; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMORHEOLOGY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; STATISTICS, NONPARAMETRIC; TACROLIMUS; VASCULAR DISEASES; VASODILATION;

EID: 84884615797     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000237     Document Type: Article

References (41)

1. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol. 2009; 4(12): 2029-2034.
2. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000; 57(1): 307-313.
3. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988; 84(6): 985-992.
4. Lamas S. Cellular mechanisms of vascular injury mediated by calcineurin inhibitors. Kidney Int. 2005; 68(2): 898-907.
5. Ponticelli C, Montagnino G, Aroldi A, Angelini C, Braga M, Tarantino A. Hypertension after renal transplantation. Am J Kidney Dis. 1993; 21(5)(Suppl 2): 73-78.
6. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of FK506 and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with FK506. J Heart Lung Transplant. 1999; 18: 336-345.
7. Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000; 6(5): 521-530.
8. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000; 57(3): 1100-1106.
9. Ovuworie CA, Fox ER, Chow CM, et al. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation. 2001; 72(8): 1385-1388.
10. Oflaz H, Turkmen A, Kazancioglu R, et al. The effect of calcineurin inhibitors on endothelial function in renal transplant recipients. Clin Transplant. 2003; 17(3): 212-216.
11. Dusting GJ, Akita K, Hickey H, Smith M, Gurevich V. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br J Pharmacol. 1999; 128(2): 337-344.
12. Schut NH, Bilo HJ, Popp-Snijders C, Goedhart PT, Wilmink JM. Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal transplant recipients: effects of intervention with fish oil and corn oil. Scand J Clin Lab Invest. 1993; 53(5): 499-506.
13. Linde T, Sandhagen B, Backman U, Fellstrom B. Altered flow properties of blood and increased plasma fibrinogen in cyclosporin-treated renal allograft recipients. Nephrol Dial Transplant. 1999; 14(6): 1525-1529.
14. Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis. 1999; 146(1): 161-165.
15. Ernst E, Koenig W. Hemorheology, thrombogenesis, and atherosclerosis. Semin Thromb Hemost. 1993; 19(2): 99-103.
16. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997; 96(1): 168-173.
17. Zanazzi M, Fatini C, Farsetti S, et al. Blood rheology and renal transplantation: an intriguing relationship for assessing cardiovascular risk. Transplant Proc. 2010; 42(4): 1383-1384.
18. Hardeman MR, Goedhart PT, Dobbe JG, Lettinga KP. Laser assisted optical rotational cell analyzer (L. O. R. C. A): a new instrument for measurement of various structural hemorheological parameters. Clin Hemorheol. 1994; 14: 605-618.
19. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middleaged healthy men. J Am Coll Cardiol. 2005; 45(12): 1980-1986.
20. Hausberg M, Kisters K, Kosch M, Rahn KH, Barenbrock M. Flow-mediated vasodilation and distensibility of the brachial artery in renal allograft recipients. Kidney Int. 1999; 55(3): 1104-1110.
21. Calo L, Semplicini A, Davis PA, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transpl Int. 2000; 13(S1)(Suppl 1): 413-418.
22. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992; 340(8833): 1430-1432.
23. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation. 1993; 88(5 Pt 1): 2149-2155.
24. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993; 88(6): 2510-2516.
25. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992; 69(19): 1596-1601.
26. Higashi Y, Sasaki S, Nakagawa K, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol. 2000; 35(2): 284-291.
27. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol. 1997; 29(5): 964-968.
28. Yilmaz MI, Carrero JJ, Martin-Ventura JL, et al. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clin J Am Soc Nephrol. 2010; 5(7): 1174-1181.
29. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95(5): 1126-1131.
30. Akita K, Dusting GJ, Hickey H. Suppression of nitric oxide production by cyclosporin A and FK506A in rat vascular smooth muscle cells. Clin Exp Pharmacol Physiol. 1994; 21(3): 231-233.
31. Inauen W, Staubli M, Descoeudres C, Galeazzi RL, Straub PW. Erythrocyte deformability in dialysed and non-dialysed uraemic patients. Eur J Clin Invest. 1982; 12(2): 173-176.
32. Baskurt OK, Senturk UK, Dayan N, et al. Cyclosporin A affects red blood cell deformability in vivo but not in vitro in guinea pig. J Pharmacol Exp Ther. 1995; 274(3): 1438-1442.
33. Hardeman MR, Meinardi MM, Ince C, Vreeken J. Red blood cell rigidification during cyclosporin therapy: a possible early warning signal for adverse reactions. Scand J Clin Lab Invest. 1998; 58(8): 617-623.
34. Schut NH, Hardeman MR, Wilmink JM. Decrease of erythrocyte deformability in cyclosporine-treated renal transplant patients: correction with fish oil as well as corn oil. Transpl Int. 1992; 5(Suppl 1): S536-S538.
35. Chmiel B, Karkoszka H, Cierpka L, Wiecek A. Rheological properties of red blood cells in kidney transplant recipients: the role of lipid profile and type of immunosuppression. Transplant Proc. 2005; 37(4): 1885-1888.
36. Vaya A, Simo M, Santaolaria M, Todoli J, Aznar J. Red blood cell deformability in iron deficiency anaemia. Clin Hemorheol Microcirc. 2005; 33(1): 75-80.
37. Ejima J, Ijichi T, Ohnishi Y, et al. Relationship of high-density lipoprotein cholesterol and red blood cell filterability: crosssectional study of healthy subjects. Clin Hemorheol Microcirc. 2000; 22(1): 1-7.
38. Linde T, Sandhagen B, Hagg A, Morlin C, Danielson BG. Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study. J Hum Hypertens. 1996; 10(3): 199-205.
39. Shand BI. Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension. J Hum Hypertens. 2000; 14(5): 305-309.
40. Kohno M, Murakawa K, Yasunari K, et al. Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metabolism. 1997; 46(3): 287-291.
41. Bor-Kucukatay M, Wenby RB, Meiselman HJ, Baskurt OK. Effects of nitric oxide on red blood cell deformability. Am J Physiol Heart Circ Physiol. 2003; 284(5): H1577-H1584.